Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Image 3-TABRECTA
It will be available as oral film-coated tablets in 150mg and 200mg strengths. Credit: Novartis Pharmaceuticals Corporation.